Jeffrey Skolnik

Jeffrey Skolnik

Company: Inovio Pharmaceuticals

Job title: Vice President

Bio:

Dr. Skolnik oversees all of Inovio’s cancer immunotherapy programs, as well as those for several infectious diseases. Dr. Skolnik was previously at Tetralogic Pharmaceuticals, where he was Vice President of Clinical Research and later Chief Medical Officer, and oversaw all clinical programs in oncology, infectious diseases and dermatology. He was also a Medical Affairs lead in oncology at GSK and held several positions at AstraZeneca including Senior Director for both early and late stage compounds. Dr. Skolnik is also a practicing pediatric Hematologist-Oncologist, and has published several papers regarding pediatric oncology trial design.

Seminars:

PANEL DISCUSSION: An Overview of Emerging Therapeutic Targets 5:15 pm

Examine the current treatment options and emerging targeted therapies If targeted therapies show limited efficacy as single agents, can the combination of several targeted therapies be of benefit to GBM patients? Additional research is urgently required to identify therapeutic targets in GBM: How can the industry design novel therapeutic strategies for the treatment of GBM?Read more

day: Day One

Empower the Immune System to Treat Glioblastoma: DNA as Medicine 2:15 pm

Explore DNA medicines that have the potential to create robust, antigen-specific T cell responses Evaluate Inovio’s DNA medicine, INO-5401 has promising, early data in GBM showing early efficacy, and immunogenicity Discuss Inovio’s DNA medicine, its technology, and other promising approaches to GBM therapy will be discussedRead more

day: Day One

PANEL DISCUSSION: Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Glioblastoma 5:15 pm

Debate the common challenges with moving GBM clinical trials forward What can we learn from the plethora of failed phase 2 trials? With a high failure rate of phase 3 glioblastoma trials, panellists examine the need for greater reliability of earlier studiesRead more

day: Day Two

Clinical Case Study: Inovio’s Innovative Combination Trial 4:45 pm

Optimizing T cell-generating therapies in combination with PD-1/PD-L1 inhibitors for GBM Overview of the INO-5401 clinical trial and challenges to overcome in translation to phase 2 trialsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.